Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. More Details
Excellent balance sheet with high growth potential.
Share Price & News
How has Arcturus Therapeutics Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ARCT's weekly volatility has decreased from 19% to 11% over the past year.
7 Day Return
1 Year Return
Return vs Industry: ARCT underperformed the US Biotechs industry which returned 19.3% over the past year.
Return vs Market: ARCT underperformed the US Market which returned 48.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Arcturus Therapeutics Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StInvestors Who Bought Arcturus Therapeutics Holdings (NASDAQ:ARCT) Shares Three Years Ago Are Now Up 671%
1 month ago | Simply Wall StIs Arcturus Therapeutics Holdings (NASDAQ:ARCT) A Risky Investment?
2 months ago | Simply Wall StHow Much Are Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Insiders Spending On Buying Shares?
Is Arcturus Therapeutics Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ARCT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ARCT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ARCT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ARCT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARCT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ARCT is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.3x).
How is Arcturus Therapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARCT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ARCT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ARCT's is expected to become profitable in the next 3 years.
Revenue vs Market: ARCT's revenue (41.2% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: ARCT's revenue (41.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARCT's Return on Equity is forecast to be high in 3 years time
How has Arcturus Therapeutics Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARCT is currently unprofitable.
Growing Profit Margin: ARCT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ARCT is unprofitable, and losses have increased over the past 5 years at a rate of 42.7% per year.
Accelerating Growth: Unable to compare ARCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.5%).
Return on Equity
High ROE: ARCT has a negative Return on Equity (-18.19%), as it is currently unprofitable.
How is Arcturus Therapeutics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: ARCT's short term assets ($467.8M) exceed its short term liabilities ($49.5M).
Long Term Liabilities: ARCT's short term assets ($467.8M) exceed its long term liabilities ($30.4M).
Debt to Equity History and Analysis
Debt Level: ARCT's debt to equity ratio (3.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ARCT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARCT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ARCT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 56.4% each year
What is Arcturus Therapeutics Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARCT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARCT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joe Payne (48 yo)
Mr. Joseph E. Payne, also known as Joe, M.Sc., has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. ...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD1.17M) is below average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
Experienced Management: ARCT's management team is considered experienced (2.7 years average tenure).
Experienced Board: ARCT's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.3%.
Arcturus Therapeutics Holdings Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Arcturus Therapeutics Holdings Inc.
- Ticker: ARCT
- Exchange: NasdaqGM
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$836.985m
- Shares outstanding: 26.32m
- Website: https://www.arcturusrx.com
Number of Employees
- Arcturus Therapeutics Holdings Inc.
- 10628 Science Center Drive
- Suite 250
- San Diego
- United States
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC dev...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/11 03:35|
|End of Day Share Price||2021/05/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.